Coadministration of (-)-OSU6162 with L-DOPA normalizes preproenkephalin mRNA expression in the sensorimotor striatum of primates with unilateral 6-OHDA lesions

Experimental Neurology

Volumn 169, Issue 1, 2001, Pages 122-134

  Pirker, Walter ^a,b   Tedroff, Joakim ^a   Pontén, Henrik ^c   Gunne, Lars ^d   Andrén, Per E ^d   Hurd, Yasmin L ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

Basal ganglia; In situ hybridization; Monkey; Opioid neuropeptide; Parkinson's disease; Prodynorphin

Indexed keywords

3 [3 (METHYLSULFONYL)PHENYL] 1 PROPYLPIPERIDINE; CARBIDOPA; DOPAMINE; LEVODOPA; OXIDOPAMINE; PREPROENKEPHALIN; PRODYNORPHIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; CONTROLLED STUDY; DOPAMINE UPTAKE; HISTOCHEMISTRY; IN SITU HYBRIDIZATION; MONKEY; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REGULATORY MECHANISM; STRIATONIGRAL DEGENERATION;

EID: 0035018154     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.2001.7647     Document Type: Article

References (54)

1. The functional anatomy of basal ganglia disorders
2. Functional architecture of basal ganglia circuits: Neural substrates of parallel processing
3. Effect of chronic typical and atypical neuroleptic treatment on proenkephalin mRNA levels in the striatum and nucleus accumbens of the rat
4. Molecular aspects of neuropeptide regulation and function in the corpus striatum and nucleus accumbens
5. Behavioural analysis of unilateral monoamine depletion in the marmoset
6. Striatal changes in preproenkephalin mRNA levels in parkinsonian monkeys
7. Cellular localization of enkephalin gene expression in MPTP-treated cynomolgus monkeys
8. Role of a 35 kDa fos-related antigen (FRA) in the long-term induction of striatal dynorphin expression in the 6-hydroxydopamine lesioned rat
9. Opioid peptide precursor expression in animal models of dystonia secondary to dopamine-replacement therapy in Parkinson's disease
10. Neuropeptide messenger RNA expression in the 6-hydroxydopaminelesioned rat striatum reinnervated by fetal dopaminergic transplants: Differential effects of the grafts on preproenkephalin, preprotachykinin and prodynorphin messenger RNA levels
11. A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: Implications for future strategies in treatment
12. Primate models of movement disorders of basal ganglia origin
13. Enhancement of the behavioral response to apomorphine administration following repeated treatment in the 6-hydroxydopamine-lesioned rat is temporally correlated with a rise in striatal preproenkephalin-B, but not preproenkephalin-A, gene expression
14. Topographical organization of opioid peptide precursor gene expression following repeated apomorphine treatment in the 6-hydroxydopamine-lesioned rat
15. (-)-OSU6162 inhibits levodopa-induced dyskinesias in a monkey model of Parkinson's disease
16. Dopamine autoreceptor function is lost in advanced Parkinson's disease
17. Dopaminergic modulation of striatal neuropeptides: Differential effects of D1 and D2 receptor stimulation on somatostatin, neuropeptide Y, neurotensin, dynorphin and enkephalin
18. Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats
19. Is levodopa toxic?
20. Ageing and Parkinson's disease: Substantia nigra regional selectivity
21. D1 and D2 dopamine receptor regulated gene expression of striatonigral and striatopallidal neurons
22. Dopamine differentially regulates dynorphin, substance P and enkephalin expression in striatal neurons: In situ hybridization histochemistry analysis
23. Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease
24. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat
25. Effects of L-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum
26. Parkinsonism treated with levodopa: Progression and mortality
27. Effects of long-term administration of antipsychotic drugs on enkephalinergic neurons
28. Isolation and structural organization of the human preproenkephalin B gene
29. Differential messenger RNA expression of prodynorphin and proenkephalin in the human brain
30. L-DOPA reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP
31. 3H]CFT
32. Phenotypical characterization of the rat striatal neurons expressing the D1 dopamine receptor gene
33. Dopamine receptor gene expression by enkephalin neurons in rat forebrain
34. Influence of nigrostriatal dopaminergic tone on the biosynthesis of dynorphin and enkephalin in rat striatum
35. On the role of enkephalin cotransmission in the GABAergic striatal efferents to the globus pallidus
36. Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: Comparison with L-DOPA therapy
37. Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists
38. Localization of striatal opioid gene expression, and its modulation by the mesostriatal dopamine pathways: An in situ hybridization study
39. 11C-methyl]-(-)-OSU6162, its regional brain distribution and some pharmacological effects of (-)-OSU6162 on the dopaminergic system studied in the rhesus monkey by positron emission tomography
40. Isolation and structural organization of the human preproenkephalin gene
41. Dopaminergic neurons of the substantia nigra modulate preproenkephalin A gene expression in rat striatal neurons
42. Levodopa-induced dyskinesia: Review, observations, and speculations
43. Dopaminergic regulation of peptide gene expression in the striatum of normal and parkinsonian monkeys
44. L-Dopa and dyskinesias in normal monkeys
45. Differential dopaminergic regulation of proenkephalin and prodynorphin mRNAs in the basal ganglia of rats
46. Differential regional effects of long-term L-DOPA treatment on preproenkephalin and preprotachykinin gene expression in the striatum of 6-hydroxydopaminelesioned rat
47. Striatal preproenkephalin gene expression is upregulated in acute but not chronic Parkinsonian monkeys: Implications for the contribution of the indirect striatopallidal circuit to Parkinsonian symptomatology
48. Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: Synthesis and structure-activity relationships
49. Effects of the substituted (S)-3-phenylpiperidine (-)-OSU6162 on PET measurements in subhuman primates: Evidence for tone-dependent normalization of striatal dopaminergic activity
50. Rostrocaudal subregional differences in the response of enkephalin, dynorphin and substance P synthesis in the rat nucleus accumbens to dopamine depletion
51. Increase of enkephalin and decrease of substance P immunoreactivity in the dorsal and ventral striatum of the rat after midbrain 6-hydroxydopamine lesions
52. Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain
53. Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA